MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Elodie MailleSolenn BrosseauVincent HanouxChristian CreveuilClaire DanelEmmanuel BergotArnaud ScherpereelJulien MazièresJacques MargeryLaurent GreillierClarisse Audigier-ValetteDenis Moro-SibilotOlivier MolinierRomain CorreIsabelle MonnetValérie GounantAlexandra LanglaisFranck MorinGuénaelle LevalletGérard ZalcmanPublished in: British journal of cancer (2019)
MST1/hippo kinase expression loss is predictive of poor prognosis in MPM patients, leading to nuclear YAP accumulation and electing YAP as a putative target for therapeutic intervention in human MPM.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- dna methylation
- randomized controlled trial
- newly diagnosed
- genome wide
- ejection fraction
- endothelial cells
- chronic kidney disease
- gene expression
- peritoneal dialysis
- transcription factor
- prognostic factors
- copy number
- patient reported outcomes
- tyrosine kinase
- protein kinase
- induced pluripotent stem cells
- pluripotent stem cells